Radiolabeled monoclonal antibodies in the diagnosis and treatment of malignant melanoma

Journal Article · Sun Oct 01 00:00:00 EDT 1989 · Seminars in Nuclear Medicine; (USA)

DOI:https://doi.org/10.1016/S0001-2998(89)80019-4· OSTI ID:5226479

Divgi, C R; Larson, S M ^[1]

---

1. Memorial Sloan-Kettering Cancer Center, New York, NY (USA)

The use of antibodies directed against tumors has found increasing usefulness after the discovery by Kohler and Milstein of hybridoma technology, which made it possible to obtain monoclonal antibody (MoAb) that reacted specifically against a particular epitope on a particular antigen site. Relative tumor specificity and a lack of significant toxicity, together with the ability to link radionuclides (both halogens and metals) without significant deterioration of biologic behavioral characteristics such as immunoreactivity, have enabled widespread use of radiolabeled MoAbs in several malignancies, including and especially malignant melanoma. There is a significant body of data indicating that radiolabeled MoAbs directed against melanoma-associated antigens have an important role in the detection and therapy of metastatic malignant melanoma. Detection of visceral disease, while currently suboptimal, will in the future improve with optimization of SPECT imaging using 99mTc-labeled MoAb Fab fragments. This may result in an attenuated or absent antimouse response, especially after one injection, unless of course coinfused with either specific and/or nonspecific intact immunoglobulin (Ig). Radiolabeled fragments play an important role in radioimmunotherapy in metastatic melanoma. This role may be enhanced by the development of newer chelating agents that will decrease nonspecific hepatic uptake of radionuclide, enabling the use of beta-emitting radiometals such as 90Y. The recent report demonstrating diminished hepatic uptake of 99mTc-labeled anti-high molecular weight antigen (HMWA) Fab shows promise, since the same labeling technique can be used to deliver radiotherapeutic agents such as 186Re, which may be labeled to MoAb with methods similar to those used for 99mTc.82 references.

• OSTI ID: 5226479
• Journal Information: Seminars in Nuclear Medicine; (USA), Vol. 19:4, Issue 4; ISSN 0001-2998
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MELANOMAS
DIAGNOSIS
RADIOIMMUNOTHERAPY
MONOCLONAL ANTIBODIES
SPECIFICITY
ISOMERIC NUCLEI
MAN
RADIOIMMUNOSCINTIGRAPHY
REVIEWS
RHENIUM 186
TECHNETIUM 99
YTTRIUM 90
ANIMALS
ANTIBODIES
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC TECHNIQUES
DISEASES
DOCUMENT TYPES
ELECTRON CAPTURE RADIOISOTOPES
HEAVY NUCLEI
HOURS LIVING RADIOISOTOPES
IMMUNOLOGY
IMMUNOTHERAPY
INTERMEDIATE MASS NUCLEI
ISOMERIC TRANSITION ISOTOPES
ISOTOPE APPLICATIONS
ISOTOPES
MAMMALS
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ODD-ODD NUCLEI
PRIMATES
RADIOIMMUNODETECTION
RADIOIMMUNOLOGY
RADIOISOTOPE SCANNING
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
RHENIUM ISOTOPES
SCINTISCANNING
TECHNETIUM ISOTOPES
THERAPY
TRACER TECHNIQUES
VERTEBRATES
YEARS LIVING RADIOISOTOPES
YTTRIUM ISOTOPES
550601* - Medicine- Unsealed Radionuclides in Diagnostics
550604 - Medicine- Unsealed Radionuclides in Therapy- (1980-)